Literature DB >> 33083806

Structural impact on SARS-CoV-2 spike protein by D614G substitution.

Jun Zhang, Yongfei Cai, Tianshu Xiao, Jianming Lu, Hanqin Peng, Sarah M Sterling, Richard M Walsh, Sophia Rits-Volloch, Piotr Sliz, Bing Chen.   

Abstract

Substitution for aspartic acid by glycine at position 614 in the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing pandemic, appears to facilitate rapid viral spread. The G614 variant has now replaced the D614-carrying virus as the dominant circulating strain. We report here cryo-EM structures of a full-length S trimer carrying G614, which adopts three distinct prefusion conformations differing primarily by the position of one receptor-binding domain (RBD). A loop disordered in the D614 S trimer wedges between domains within a protomer in the G614 spike. This added interaction appears to prevent premature dissociation of the G614 trimer, effectively increasing the number of functional spikes and enhancing infectivity. The loop transition may also modulate structural rearrangements of S protein required for membrane fusion. These findings extend our understanding of viral entry and suggest an improved immunogen for vaccine development.

Entities:  

Year:  2020        PMID: 33083806      PMCID: PMC7574265          DOI: 10.1101/2020.10.13.337980

Source DB:  PubMed          Journal:  bioRxiv


  2 in total

1.  35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope.

Authors:  Xiaofei Wang; Xiangyu Chen; Jiaxing Tan; Shuai Yue; Runhong Zhou; Yan Xu; Yao Lin; Yang Yang; Yan Zhou; Kai Deng; Zhiwei Chen; Lilin Ye; Yongqun Zhu
Journal:  Cell Host Microbe       Date:  2022-03-29       Impact factor: 31.316

2.  The Delta variant SARS-CoV-2 spike protein uniquely promotes aggregation of pseudotyped viral particles.

Authors:  Jennifer D Petersen; Jianming Lu; Wendy Fitzgerald; Fei Zhou; Paul S Blank; Doreen Matthies; Joshua Zimmerberg
Journal:  bioRxiv       Date:  2022-04-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.